Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot and infusion combo tackles tough blood cancer

NCT ID NCT06223516

Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests an experimental drug called etentamig (ABBV-383) in about 55 adults with multiple myeloma that has returned or not responded to prior treatments. The drug is given as a shot under the skin or through an IV. The main goals are to check safety, side effects, and how the drug moves through the body. This is not a cure, but aims to control the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

60 people

The number who actually took part.

Started

Jun 2024

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance of \<= 2. * Participants with relapsed or refractory multiple myeloma who have received 3-5 prior lines of therapies and with prior triple class exposure including a proteasome inhibitor, anti-CD38 monoclonal antibody and an immunomodulatory drug. * Must be naïve to treatment with ABBV-383. Exclusion Criteria: \- Received B-cell maturation antigen (BCMA)xCD3 bispecific antibody.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple myeloma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple myeloma

Contacts and locations

Locations

  • Atrium Health Wake Forest Baptist Medical Center /ID# 260807

    Winston-Salem, North Carolina, 27157, United States

  • Hadassah Medical Center-Hebrew University /ID# 261446

    Jerusalem, Jerusalem, 91120, Israel

  • Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital /ID# 265286

    Nagoya, Aichi-ken, 466-8650, Japan

  • Kindai University Hospital /ID# 266016

    Sakai-shi, Osaka, 590-0197, Japan

  • Mayo Clinic - Rochester /ID# 262807

    Rochester, Minnesota, 55905-0001, United States

  • Mayo Clinic Arizona /ID# 260799

    Phoenix, Arizona, 85054, United States

  • Mayo Clinic Hospital Jacksonville /ID# 262808

    Jacksonville, Florida, 32224, United States

  • Sylvester Comprehensive Cancer Center /ID# 260798

    Miami, Florida, 33136-1002, United States

  • Tel Aviv Sourasky Medical Center /ID# 261525

    Tel Aviv, Tel Aviv, 6423906, Israel

  • The Chaim Sheba Medical Center /ID# 261699

    Ramat Gan, Tel Aviv, 5265601, Israel

  • Universitaetsklinikum Frankfurt /ID# 260442

    Frankfurt am Main, Hesse, 60590, Germany

  • Universitaetsklinikum Hamburg-Eppendorf /ID# 260444

    Hamburg, 20246, Germany

  • Universitaetsklinikum Koeln /ID# 260445

    Cologne, North Rhine-Westphalia, 50937, Germany

  • University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 261050

    Ann Arbor, Michigan, 48109, United States

  • Wisconsin Medical Center /ID# 261085

    Milwaukee, Wisconsin, 53226, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.